Kornimate/medical-research-clean huggingface dataset:
prevention of acute voiding difficulty after radical proctectomy

Conditions: Rectal Cancer; Urinary Retention

Summary: various adrenergic blockers are used for acute voiding difficulty after proctectomy. recently, a selective alpha5-adrenergic blocker, tamsulosin has been reported to have benefit in reducing urinary symptom score and in reducing the rate of intermittent self-catheterization for patients with rectal cancer after radical proctectomy. this study is to evaluate the efficacy of pharmacologic prevention to ameliorate the incidence of postoperative urinary dysfunction.

acute voiding difficulty is caused from damage to pelvic sympathetic nerve after rectal surgery, and usually resolved spontaneously within several months after the surgery. however, acute voiding difficulty results in prolonged insertion of urinary catheter and is associated risk for urinary tract infection. various adrenergic blockers are used for acute voiding difficulty after proctectomy. recently, a selective alpha5-adrenergic blocker, tamsulosin has been reported to have benefit in reducing urinary symptom score and in reducing the rate of intermittent self-catheterization for patients with rectal cancer after radical proctectomy. this study is to evaluate the efficacy of pharmacologic prevention to ameliorate teh incidence of postoperative urinary dysfunction.

Eligibility criteria:
inclusion criteria: * patients between 20-80 years old in general good health * patient willing to participate in the study * patient who understands and accepts to sign the informed consent form * patient who received proctectomy for rectal cancer located 15 cm or less of the anal verge exclusion criteria: * documented problem of preoperative urinary dysfunction * any post-surgery change in patient condition which requires insertion of urinary catheter after surgery * past history of recurrent urinary tract infection or malignancy of urinary system organs * past history of surgery for urinary system organs * current administration of finasteride or dutasteride * liver dysfunction (sgot or sgpt 100 iu/l or more) * kidney dysfunction (serum creatinine 3mg/dl or more)
external counterpulsation (ecp) for the promotion of collateral growth in patients with coronary artery disease

Conditions: Coronary Artery Disease

Summary: the purpose of this study in humans with stable coronary artery disease (cad) treatable by percutaneous coronary intervention (pci) is to evaluate the efficacy of external counterpulsation (ecp) with regard to the promotion of coronary collateral growth.

alternative strategies for the promotion of coronary collaterals (arteriogenesis) are a promising therapeutic alternative for at least 20% of all patients with coronary artery disease (cad). beside growth factors, physical exercise has been shown to improve coronary collateral function. extracorporal counterpulsation (ecp) mimics physical exercise in a standardized way. before and after ecp treatment, a quantitative invasive assessment of absolute collateral flow (by calculating the cfi, i.e. collateral flow index) and myocardial perfusion is performed (with calculation of the cpi, i.e. collateral perfusion index and mpr, i.e. myocardial perfusion reserve). the study setting is single-blinded, sham-controlled and proceptive .

Eligibility criteria:
inclusion criteria: * age \> 18 years old * 1- to 3-vessel coronary artery disease (cad) * stable angina pectoris * at least 1 stenotic lesion suitable for pci within the next 4 weeks * no q-wave myocardial infarction in the area undergoing cfi measurement * written informed consent to participate in the study exclusion criteria: * patients admitted as emergencies * acute myocardial infarction within the last 3 months * unstable cad * cad treated best by cabg * coronary stenotic lesion to be treated ad-hoc or within \< 4 weeks * severe valve disease * pulmonary artery hypertension * congestive heart failure * atrial fibrillation * thrombophlebitis and/or deep vein thrombosis * occlusive peripheral artery disease * abdominal aortic aneurysm

Keywords: cad ecp cfi cpi mpr
pilot trial of phototherapy for acute depression in hospitalized cystic fibrosis patients

Conditions: Depression; Cystic Fibrosis

Summary: the purpose of this study is to determine whether bright light phototherapy can improve depressive symptoms in hospitalized patients with cystic fibrosis (cf) with subsequent effects on quality of life and illness recovery. it is hypothesized that phototherapy will improve depressive symptoms and decrease length of stay in depressed patients with cf who are hospitalized.

adults and adolescent with cf who are admitted to the hospital for pulmonary exacerbations will be enrolled. subjects will use a sun touch plus light box that emits 10,000 lux at a minimum distance of 60-80 cm away upon first awakening. light exposure will last for 30 minutes each day over one week. nursing staff will ensure compliance and a light sensor attached to the light box will measure use as well. there will not be a placebo during this pilot trial due to recruitment concerns for the sample size required for a single center placebo controlled trial. all light boxes will be sterilized between patient use. vitamin d levels will be recorded at enrollment from routine clinical measurement. light boxes do not emit uv light and have a negative ionizer. depression screening: quick inventory of depressive symptomatology self report and clinician administered survey (qids-sr and qids-c) will be administered at admission (day 0) and completion of light therapy (day 7) to look at changes in depressive symptoms. the qids assesses all the criterion symptom domains designated by the american psychiatry association diagnostic and statistical manual of mental disorders - 4th edition (dsm-iv) to diagnose a major depressive episode. the qids is sensitive to change, with medications, psychotherapy, or somatic treatments, making it useful for research purposes. the psychometric properties of both the qids has been established in various study samples. cronbach's alpha was 0.85 (qids-c16) and 0.86 (qids-sr16) in a reliability study by triveldi in 2004. quality of life scoring: the cf questionnaire revised (cfq-r) will be administered simultaneously with the qids at days 0 \& 7 as a measure of health related quality of life (hrqol). this is a well validated measure in the cf population for research studies (riekert et al., 2007).

Eligibility criteria:
inclusion criteria: * patients with cf greater than 12 years of age * pulmonary exacerbation exclusion criteria: * planned admission less than 24 hours * suicidal ideation * bipolar depression * known retinal disorder/photosensitivity * light induced epilepsy or migraines * age less than 12 years of age

Keywords: phototherapy
a phase ii exploratory, multicentre, open-label, non-comparative study of zd1839 (iressa) and radiotherapy in the treatment of patients with glioblastoma multiforme

Conditions: Glioblastoma

Summary: the purpose of the study is to determine the efficacy of gefitinib (iressatm) in combination with radiotherapy on patients with glioblastoma multiforme.


Eligibility criteria:
inclusion criteria: * signed informed consent * histologically-or cytologically-confirmed glioblastoma multiforme * age 18 years or older exclusion criteria: * have had prior radiation therapy, immunotherapy, gene therapy and/or chemotherapy for the glioblastoma * co-existing malignancies or malignancies diagnosed within the last 5 years with the exception of basal cell carcinoma or cervical cancer in situ * known severe hypersensitivity to zd1839 or any of the excipients of this product.

Keywords: glioblastoma multiforme brain tumour
tumor associated neutrophils as a biomarker of chemo-immunotherapy response in locally advanced non-small cell lung cancer : a model based on neoadjuvant strategy

Conditions: Non-Small Cell Lung Cancer

Summary: evaluate the predictive value of circulating neutrophil dna methylation profiles, identified from the alcina 2 cohort, on pre-treatment blood samples (t0), for the histological response to neoadjuvant chemo-immunotherapy in patients with resectable non-small cell lung cancer (nsclc)


Eligibility criteria:
inclusion criteria: * age ≥ 18 years. * resectable non-small cell lung cancer (nsclc), stage iia to iiib. * lymph node status obtained by positron emission tomoscintigraphy (pet)-scanner, confirmation of lymph node status by optional histological sampling (mediastinoscopy, thoracoscopy, echo-endoscopy). * no secondary lesions in the cerebrum or extra-cerebrum confirmed on brain mri, pet scanner +/- injected cerebro-thoraco-abdomino-pelvic scanner. * neoadjuvant immunochemotherapy strategy validated by a multidisciplinary consultation meeting (rcp) prior to the start of treatment. * lung function compatible with thoracic surgery, patient meets surgical and anesthetic criteria for operability * measurable disease according to recist criteria version 1.1 exclusion criteria: * previous systemic treatment for the same cbnpc. * diagnosis of another solid tumor within the last 3 years, ‡ excluding non melanoma cutaneous and cervical carcinomas . * contraindication to immunotherapy. * non-objection to participate in research not collected. * patients unable to read and/or write. * inability to monitor patient during study period * persons unable to express their consent. * not affiliated to a social security scheme. * persons under court protection. * persons participating in another research study with an ongoing exclusion period. * pregnant women
detect: target volume for rectal endoluminal radiation boosting

Conditions: Rectal Cancer

Summary: the aim of the study is to provide prospective data regarding microscopic tumor spread in all directions from the macroscopic tumor in pathology specimens, as seen by eye, and on imaging to define the target volume for endoluminal radiation boosting in rectal cancer patients.

this study is a prospective multicentre cohort trial in ≥50 patients with a residual yct1-3n0 tumor after neoadjuvant chemoradiotherapy or radiotherapy for rectal adenocarcinoma at least 6 weeks after the neoadjuvant treatment. in addition to standard workup and treatment (e.g. a flexible endoscopy and an mri scan at 6-8 weeks post-neoadjuvant therapy), patients will undergo pre-operatively, after induction of general anaesthesia, an endorectal ultrasound and rigid rectoscopy as study procedures if these procedures are not already part of standard workup. furthermore, the pathological specimens of some patients will be scanned using mr imaging during certain parts of the pathological process. objectives include determining the maximum distance of microscopic tumor spread per patient in all directions, creating a tissue deformation model to account for changes due to e.g. fixation and pathological processing, using this tissue deformation model to translate the microscopic tumor spread back to the in vivo situation (e.g. back to in vivo mri scans, 3d endo-ultrasounds), and evaluating/determining risk factors for the presence and/or extent of microscopic tumor spread. this data will be used for target volume definition in rectal endoluminal radiation boosting.

Eligibility criteria:
inclusion criteria: * ≥18 years of age and capable of giving informed consent. * yct1-3n0(\*) residual(\*\*) histology confirmed rectal adenocarcinoma after neoadjuvant radiotherapy or long-course chemoradiotherapy for which patients will undergo tme surgery. * minimal interval between end of neoadjuvant chemoradiotherapy or radiotherapy: 6 weeks. (\*)= as determined by clinical assessment (digital rectal examination, endoscopy with or without biopsy) and/or mri. biopsy/histology around the time of diagnosis is adequate; no biopsy/histology is needed after neoadjuvant therapy. (\*\*)= including tumor regrowths/local recurrence after an initial clinical complete response and a "watch and wait" approach. these patients will also be included after the local recurrence has been determined using endoscopy and/or mri. exclusion criteria: * patient has received brachytherapy as part of neoadjuvant treatment. * \<18 years of age or incapable of giving informed consent. * patient has not been treated with neoadjuvant radiotherapy or long-course chemoradiotherapy. * patient will not undergo tme surgery for a yct1-3n0 residual histology confirmed rectal adenocarcinoma. * interval between end of neoadjuvant therapy and surgery is \<6 weeks.

Keywords: rectal cancer microscopic tumor spread target volume definition endoluminal radiation boosting
refractive accuracy of argos in conjunction with the alcon vision suite following implantation of presbyopia correcting iols

Conditions: Cataract

Summary: the objective is to assess refractive accuracy of the alcon vision suite (with argos biometer) following clareon panoptix and acrysof vivity iol implantation.

this study is a single-arm, observational study of refractive accuracy of the alcon vision suite (with argos biometer) following clareon panoptix and acrysof vivity iol implantation. subjects will be assessed at preoperatively, operatively, and 10 weeks post-operatively. clinical evaluations will include measurement of monocular and binocular visual acuity, manifest refraction, and questionnaires will also be administered.

Eligibility criteria:
inclusion criteria: subjects are eligible for the study if they meet the following criteria: note: ocular criteria must be met in both eyes. * age-related cataract surgery (or rle) patients that select clareon panoptix or acrysof vivity iol. * gender: males and females. * age: 45 or older. * patients motivated to increase spectacle independence with relatively low incidence of visual phenomena. * willing and able to provide written informed consent for participation in the study. * willing and able to comply with scheduled visits and other study procedures. * have good ocular health, with no pathology that compromises visual acuity (outside of residual refractive error). exclusion criteria: if any of the following exclusion criteria are applicable to the subject or either eye, the subject should not be enrolled in the study. * ocular comorbidity (any previous ocular surgery, any signs of retinal disease, or glaucoma etc.) that might hamper post-operative visual acuity. * irregular corneal astigmatism and keratoconus. * post refractive eyes (i.e. lasik or prk or smile). * patients with physical or intellectual disability (e.g. down's syndrome, parkinson's disease; unable to fixate). * angle kappa/chord mu ≥0.6. * higher order corneal aberrations: \> 0.6 total rms, \>0.3 coma, \>0.3 trefoil (to exclude irregular corneas). the principal investigator reserves the right to declare a patient ineligible or non-evaluable based on medical evidence that indicates they are unsuitable for the trial. pregnancy has a known effect on the stability of refractions and visual acuity. as such, subjects who become pregnant during the study will not be discontinued but their data may be excluded from analyses of effectiveness.
analysis of the effectiveness and safety of rirs under local anesthesia and its influencing factors

Conditions: Urolithiasis

Summary: retrograde intrarenal surgery (rirs) is a well-established technique and is the first-line treatment option for upper urinary tract stones \<2cm. currently, most ureteroscopic procedures are performed under general or epidural anesthesia, both of which are safe and feasible. in recent years, more and more studies have shown that retrograde intrarenal surgery (rirs) under local anesthesia is safe and feasible. however, we can see that the current studies on rirs under local anesthesia are mostly case reports, and there is a lack of systematic studies on the safety and effectiveness of rirs under local anesthesia and its influencing factors. therefore, the researchers hope to conduct a single-center prospective observational study to explore the safety, effectiveness and influencing factors of rirs under local anesthesia, so as to optimize the surgical process of rirs under local anesthesia, improve the surgical success rate and ensure surgical safety。


Eligibility criteria:
inclusion criteria: 1. kidney stones or upper ureteral stones 1-4cm; 2. age 18-70 years old; 3. american society of anesthesiologists(asa) score ⅰ, ⅱ and ⅲ; exclusion criteria: 1. surgical operations other than rirs are required for patients with middle and lower ureteral calculi; 2. there are anatomical abnormalities, such as ureteral stenosis, urine flow diversion, ectopic kidney, horseshoe kidney, duplicate kidney, etc. 3. severe heart, brain and lung diseases; 4. pregnancy.
ferric citrate in managing serum phosphorus and iron deficiency in anemic chronic kidney disease (ckd) subjects not on dialysis

Conditions: Iron Deficiency; Iron Deficiency Anemia

Summary: the purpose of this study is to determine if krx-0502 (ferric citrate) is a safe and effective treatment for the management of serum phosphorus levels and iron deficiency in anemic chronic kidney disease (ckd) stage 3-5 subjects not on dialysis. total length of treatment is approximately 12 weeks.

this is a randomized, double-blind, placebo-controlled, three-period, multi-center clinical trial. following a screening and qualification period and a two-week washout period (for those subjects entering the study on a phosphate binder), eligible subjects will be randomized in a 1:1 ratio to receive either krx-0502 (ferric citrate) or placebo for up to approximately 12 weeks. the purpose of this study is to determine if krx-0502 (ferric citrate) is a safe and effective treatment for the management of serum phosphorus levels and iron deficiency in anemic ckd subjects not on dialysis.

Eligibility criteria:
inclusion criteria: * stage iii to v chronic kidney disease * serum phosphorus 4.0-6.0 mg/dl prior to randomization * ferritin 300 ng/ml or less * transferrin saturation (tsat) 30% or less * hemoglobin \>9.0 and \<12.0 g/dl * must consume a minimum of 2 meals per day exclusion criteria: * parathyroidectomy within 24 weeks of study * gastrointestinal bleed or inflammatory bowel disease within 12 weeks of study * requirement for dialysis or kidney injury within 8 weeks of study * absolute requirement for oral iron, intravenous iron, erythropoiesis-stimulating agent, blood transfusions, and sensipar during the study * absolute requirement for calcium-, magnesium-, or aluminum-containing drugs with meals * absolute requirement for vitamin c, niacin, or nicotinamide outside of multivitamins * history of hemochromatosis * allergy to iron products * history of malignancy in last 5 years

Keywords: ckd chronic kidney disease phosphorus iron deficiency iron deficiency anemia elevated phosphorus
combined dental bleaching protocols and time required to achieve satisfactory color

Conditions: Tooth Discoloration

Summary: this parallel, randomized, and controlled clinical trial will assess the effect of a single prior session of in-office dental bleaching on time required to achieve satisfactory tooth color with at-home bleaching. participants enrolled will randomly allocated to receive or not a single session of dental bleaching with 35% hydrogen peroxide applied for 45 min. following, all participants will use customized trays filled with 10% carbamide peroxide for 1h per day until obtain satisfactory results. the primary outcome will be the number of days necessary to obtain satisfactory tooth color. furthermore, tooth sensitivity and color changes measured with spectrophotometer will be assessed.


Eligibility criteria:
inclusion criteria: * good general and oral health; * upper canines darker than the tab 2.5m2 at vita bleachedguide 3d-master® (vita-zahnfabrik, bad sackingen, germany) scale. exclusion criteria: * presence of non-treated caries or periodontal disease; * prior tooth hypersensitivity; * presence of gingival recession; * teeth with cracked enamel or any hypoplasia; * patients using oral removable or fixed orthodontic appliances; * patients were pregnant or breastfeeding.

Keywords: tooth bleaching hydrogen peroxide carbamide peroxide tooth bleaching agents
epidural association of morphine and ropivacaine for cancer pain treatment

Conditions: Cancer Pain; Opioid Use; Cost Analysis; Palliative Care; Epidural Route; Morphine-ropivacaine Association; Quality of Life; Rational Use of Medication

Summary: in 2012, more than 14 million cases of cancer were diagnosed worldwide, with the forecast for 2025 exceeding 20 million. pain is the most critical symptom that accompanies cancer. the development of disease generates the need for oncological palliative care and adequacy of the structure by public health care system. in this context, this study aims to evaluate an alternative to the treatment plans provided for in the brazilian's public health care system table. the objective is to carry out a cost-effectiveness analysis of the epidural administration of morphine and ropivacaine in patients with abdominal neoplasia, and pain that is difficult to clinically control, which leads to an improvement in the quality of life, functional conditions and survival of patients, and that reduces the cost to the brazilian's public health care system. this is a randomized clinical trial. patients will be divided into two groups: control and intervention. the control group will receive oral treatment according to the clinical protocol and therapeutic guidelines for chronic pain of the brazilian's ministry of health: morphine, pregabalin and duloxetine. the intervention group will receive an anesthetic solution containing morphine and ropivacaine for epidural administration through a surgically implanted catheter. pain, quality of life, functional capacity and survival will be evaluated using the following instruments: visual analogue scale; european organization for research and treatment of cancer quality of life questionnaire "core" 30; karnofsky performance scale; eastern cooperative oncology group scale; palliative performance scale; and palliative prognosis index. it is expected that, at the end of the study, the intervention group will represent a significant savings for the public health care system, due to the decrease in the number of hospitalizations/day and the possible complications due to the lack of effectiveness of the oral treatment. it is expected that the results found will produce scientific support to disseminate the proposed treatment plan for brazilian's public health care system patients in palliative care.


Eligibility criteria:
inclusion criteria: * patients aged between 18 and 75 years, * both sexes * diagnosed with abdominal neoplasia and with ppi \< 2.0, which indicates a survival of at least 90 days * have full cognitive conditions * patients must also have a caregiver with cognitive conditions. exclusion criteria: - patients with technical incapacity to implant the catheter will be excluded, namely: patient refusal, infection at the puncture site and hemodynamic instability.